DO53
DO53 is a serine hydrolase inhibitor that targets ABHD6, PAFAH2, PLA2G7, ABHD2 and CES1C. DO53 reduces LPS (HY-D1056A1)-induced cytokine production in the mouse brain, decreases fasting-induced refeeding behavior, and induces hypoactivity in mice. As a DAGL negative control, DO53 shows no activity against DAGLα/β in vivo, and does not affect brain lipid levels, DSE/DSI synaptic plasticity or LPS-induced anhidrosis in mice. DO53 can be used in studies related to LPS-induced neuroinflammation and fasting-induced refeeding.
For research use only. We do not sell to patients.
- CAS No.: 1848233-59-9
- Formula: C25H26F3N5O4
- Molecular Weight:517.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Phospholipase Isoforms
More
Biological Activity
Description
|
ABHD6 |
ABHD2 |
PAFAH2 |
PLA2G7 |
CES1 |
In Vitro
DO53 shows minimal inhibition of recombinant human DAGLα and mouse DAGLβ in membrane lysates from transfected HEK293T cells, with ~100-fold lower activity than DH376 and DO34[1].
DO53 inhibits carboxylesterase activity in mouse liver membrane proteome, representing a shared off-target with active triazole urea DAGL inhibitors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
DO53 (50 mg/kg; i.p.; single dose; administered 60-90 minutes prior to LPS treatment) does not modulate LPS-induced brain lipid changes or anapyrexia in male C57BL/6 mice, but does attenuate LPS-induced brain IL-1β production[1].
DO53 (50 mg/kg; i.p.; single dose) significantly reduces fasting-induced refeeding and hypolocomotes mice, indicating effects on energy balance and locomotion independent of DAGL inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male)[1]
-
Dosage:3, 10, 30 and 50 mg/kg (4 hour treatment); 50 mg/kg (2, 4, 8, or 24 hour treatment)
-
Administration:i.p.; single dose
-
Result:Did not substantially inhibit DAGLα or DAGLβ activity in mouse brain at any tested dose (3, 10, 30, 50 mg/kg) at 4 hours postdosing.
Did not inhibit DAGLα or DAGLβ activity at 50 mg/kg at any time point (2, 4, 8, 24 hours) postdosing.
Inhibited the serine hydrolases ABHD6 and PLA2G7 at all tested doses and time points.
-
Animal Model:C57BL/6 (male; LPS-induced neuroinflammation)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; single dose; administered 60-90 minutes prior to LPS treatment
-
Result:Did not alter basal brain levels of 2-AG, arachidonic acid (AA), or prostaglandin E2 (PGE2), nor suppress LPS-induced elevations in brain 2-AG or PGE2.
Did not blunt LPS-induced anapyrexia (core body temperature reduction) in mice.
Reduced LPS-induced increases in brain interleukin-1β (IL-1β) cytokine levels to a similar degree as DAGL inhibitors DH376 and DO34.
-
Animal Model:C57Bl/6J (12-week-old male)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced cumulative food intake significantly at 2 hours and 4 hours post-refeeding compared to vehicle-treated mice.
Elevated fat oxidation and suppressed carbohydrate oxidation relative to vehicle controls over the monitoring period.
Reduced normalized locomotor activity over 4 hours to approximately 40% of vehicle-treated levels.
Chemical Information
-
CAS No. 1848233-59-9
-
Molecular Weight 517.50
-
Formula C25H26F3N5O4
-
SMILES
O=C(OC(C)(C)C)N1CC(N(CC1)C(N2N=NC(C3=CC=C(C=C3)OC(F)(F)F)=C2)=O)C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
Purity & Documentation
References
[1]. Ogasawara D, et al. Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition. Proceedings of the National Academy of Sciences of the United States of America. 2016 Jan 05;113(1):26-33. [Content Brief]
[2]. Deng H, et al. Triazole Ureas Act as Diacylglycerol Lipase Inhibitors and Prevent Fasting-Induced Refeeding. Journal of medicinal chemistry. 2017 Jan 12;60(1):428-440. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)